Bliss GVS Pharma to Transfer Unclaimed Dividends & Shares to IEPF Authority
Bliss GVS Pharma will transfer unclaimed final dividends from FY 2018-19 and corresponding shares to the IEPF Authority after October 27, 2026. Shareholders must claim their shares by this date. The company also urges shareholders to complete KYC and nomination for shares held in physical form.
This is a routine regulatory compliance action concerning unclaimed dividends and shares, which is unlikely to have a significant impact on the company's operations or stock performance.
The announcement is a regulatory compliance notice regarding the transfer of unclaimed dividends and shares to the IEPF, which is a standard procedure. It does not contain positive or negative financial news.
Bliss GVS Pharma Limited has issued a notice to its shareholders regarding the compulsory transfer of unclaimed final dividends for the financial year 2018-2019 and corresponding shares to the Investor Education and Protection Fund (IEPF) Authority. This action is in accordance with Section 124(6) of the Companies Act, 2013, and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.
The company has identified dividends that have remained unpaid or unclaimed for seven consecutive years or more. Shareholders who have not claimed their final dividend for the financial year 2018-2019 onwards are informed that their shares will be transferred to the IEPF Authority on or after October 27, 2026. Shareholders have until October 27, 2026, to claim their shares by submitting a written request and necessary documents to the Registrar and Transfer Agent.
The announcement also reminds shareholders about the mandatory registration of KYC details and nomination for shares held in physical form, requesting submission of forms like ISR-1 and ISR-2. The company has provided contact details for both Bliss GVS Pharma Limited and its Registrar, MUFG Intime India Private Limited, for any queries.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.